Kodiak Sciences Inc. (KOD) — SEC Filings
Kodiak Sciences Inc. (KOD) — 16 SEC filings. Latest: 8-K (Mar 27, 2026). Includes 6 10-Q, 4 8-K, 2 DEF 14A.
View Kodiak Sciences Inc. on SEC EDGAR
Overview
Kodiak Sciences Inc. (KOD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: Kodiak Sciences Inc. filed an 8-K on December 18, 2025, reporting other events and financial statements and exhibits as of December 16, 2025. The company, incorporated in Delaware, is located at 1250 Page Mill Road, Palo Alto, CA.
Sentiment Summary
Across 16 filings, the sentiment breakdown is: 2 bearish, 14 neutral. The dominant filing sentiment for Kodiak Sciences Inc. is neutral.
Filing Type Overview
Kodiak Sciences Inc. (KOD) has filed 4 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (16)
Risk Profile
Risk Assessment: Of KOD's 13 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$173.2M |
| EPS | N/A |
| Debt-to-Equity | 8.20 |
| Cash Position | $72.0M |
| Operating Margin | N/A |
| Total Assets | $218.1M |
| Total Debt | $194.4M |
Key Executives
- Victor Perlroth, M.D.
Industry Context
Kodiak Sciences operates in the highly competitive biotechnology sector, focusing on the development of novel therapeutics. The industry is characterized by long development cycles, substantial R&D investment, and significant regulatory hurdles. Success is contingent on clinical trial outcomes and subsequent FDA approval, with many companies facing similar challenges related to funding and commercialization.
Top Tags
10-Q (4) · financials (4) · biotech (4) · Kodiak Sciences (3) · Biotechnology (2) · Clinical Stage (2) · Cash Burn (2) · Going Concern (2) · R&D Expenses (2) · Ophthalmology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $173.2M | Increased from $132.1M in 2024 for the nine months ended September 30, 2025 |
| Cash and Cash Equivalents | $72.0M | Decreased from $168.1M at December 31, 2024, as of September 30, 2025 |
| Research and Development Expenses | $136.9M | Increased from $94.3M in 2024 for the nine months ended September 30, 2025 |
| Shares Issued and Outstanding | 52,998,561 | As of September 30, 2025 |
| Total Stockholders' Equity | $23.7M | Decreased from $150.3M at December 31, 2024, as of September 30, 2025 |
| Liability related to sale of future royalties | $100.0M | Consistent across periods, indicating a long-term obligation |
| Increase in Net Loss | 31.1% | Year-over-year increase for the nine months ended September 30 |
| Increase in R&D Expenses | 45.2% | Year-over-year increase for the nine months ended September 30 |
| Net Loss (Six Months) | $111.774M | Increased from $88.156M in 2024, indicating widening losses. |
| Research and Development Expenses (Six Months) | $86.404M | Increased from $62.445M in 2024, driving higher operating costs. |
| Net Cash Used in Operating Activities (Six Months) | $63.750M | Slightly improved from $66.093M in 2024, but still a substantial outflow. |
| Shares Outstanding | 52,821,689 | As of June 30, 2025, indicating potential for future dilution. |
| Reporting Period End Date | 2025-03-31 | The 10-Q covers financial activities up to this date. |
| Reporting Period Start Date | 2025-01-01 | The 10-Q covers financial activities from this date. |
| Fiscal Year | 2024 | Period covered by the executive compensation and equity award details. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Kodiak Sciences Inc. (KOD)?
Kodiak Sciences Inc. has 16 recent SEC filings from Jan 2024 to Mar 2026, including 6 10-Q, 4 8-K, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KOD filings?
Across 16 filings, the sentiment breakdown is: 2 bearish, 14 neutral. The dominant sentiment is neutral.
Where can I find Kodiak Sciences Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Kodiak Sciences Inc. (KOD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Kodiak Sciences Inc.?
Key financial highlights from Kodiak Sciences Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KOD?
The investment thesis for KOD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Kodiak Sciences Inc.?
Key executives identified across Kodiak Sciences Inc.'s filings include Victor Perlroth, M.D..
What are the main risk factors for Kodiak Sciences Inc. stock?
Of KOD's 13 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Kodiak Sciences Inc.?
Forward guidance and predictions for Kodiak Sciences Inc. are extracted from SEC filings as they are enriched.